Peptides in Maryland: Research, Regulation and Where the Law Stands

Searches for "peptide therapy Maryland" and "peptides Maryland" usually reflect two separate questions that get tangled together: what does the published science actually report about peptide compounds, and which agencies regulate them in a given state. This page separates those questions. It describes the regulatory layers that stack on top of each other — federal, state, and professional-board — and summarises what the peer-reviewed literature has reported. This page is for educational purposes only and is not medical advice; consult a licensed physician regarding any medical question. It is also not legal advice; regulatory interpretation for a specific situation is a matter for a licensed attorney or the relevant agency.

The Federal Layer Comes First

No state statute changes the federal framework. The Food and Drug Administration approves drugs for marketing, and peptide drugs are a substantial and growing part of that pipeline. A review of the agency's 2017 approvals catalogued the peptide and peptide-derived products cleared that year and described how peptide chemistry has moved from a niche into mainstream drug development (PMID 29735913). Approved peptide medicines — including the GLP-1 receptor agonists that dominate current attention — are prescription products dispensed through licensed pharmacies.

Alongside approved drugs sits a much larger category of peptides sold with "research use only" (RUO) or "not for human consumption" labelling. RUO material is intended for laboratory work. It is not manufactured, tested, or released under the controls that apply to drugs intended for people, and it is not reviewed by the FDA for safety or efficacy in humans. That labelling is a statement about the product's regulatory status, not an endorsement or a loophole; the FDA has repeatedly signalled that labelling alone does not determine how a product is treated if it is marketed or used as a drug.

A third federal category is compounding. Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional pharmacy compounding for an identified patient pursuant to a prescription. Section 503B covers outsourcing facilities, which may compound larger batches without patient-specific prescriptions but must register with the FDA and comply with current good manufacturing practice. Both categories are constrained by which bulk substances appear on FDA lists, and the agency has moved several peptides between its categories in recent years — which is why the availability of a compounded peptide can change without any state law changing.

Compounded versions of approved peptides are not identical to the reference product. Analytical work comparing follow-on GLP-1 polypeptide products found that manufacturing process and compounding steps affected the properties and quality attributes of the resulting material (PMID 39379664). Separately, a real-world study of compounded semaglutide reported weight and body-composition changes in a clinical setting, illustrating that compounded products are being studied but on a much smaller evidence base than approved formulations (PMID 39776038).

What Is Specific to Maryland

Maryland's own contribution to this picture is administrative and professional rather than peptide-specific. Public sources support the following state-level structures:

• Maryland Board of Pharmacy. Established under the Health Occupations Article of the Maryland Code, the Board licenses pharmacists and permits pharmacies, including those that compound. It also registers non-resident pharmacies that ship into Maryland, which is the mechanism by which out-of-state compounding pharmacies fall under Maryland oversight.
• Maryland Board of Physicians. The Board licenses and disciplines physicians and certain allied professionals, and it is the body that addresses questions of standard of care, prescribing practice, and unprofessional conduct.
• Controlled Dangerous Substances registration. Maryland's Office of Controlled Substances Administration, within the Maryland Department of Health, handles state CDS registration in parallel with federal DEA registration. Most peptides discussed in wellness contexts are not scheduled controlled substances, so this layer is often not the operative one — but it exists.
• Prescription Drug Monitoring Program. Maryland operates a PDMP for monitored dispensing, which again applies primarily to controlled substances rather than to peptides generally.

Where a claim cannot be verified, it is better to say so. There is no publicly citable Maryland statute or Board regulation that singles out peptides as a distinct class with rules different from other prescription drugs or compounded preparations. Anyone who encounters a confident claim that "Maryland specifically permits" or "Maryland specifically bans" a named peptide should ask for the citation — a code section, a regulation in the Code of Maryland Regulations, or a published Board action. In the absence of that, the operative rules are the general federal and state drug, pharmacy, and medical-practice rules described above.

Telehealth and Out-of-State Prescribing

Much of the consumer-facing peptide market runs through telehealth platforms, which raises a jurisdictional question rather than a pharmacological one. The general principle across US states is that the practice of medicine occurs where the patient is located, meaning a clinician treating a Maryland resident is answerable to Maryland's medical licensing authority regardless of where the clinician sits. Maryland has enacted telehealth provisions in its Health Occupations Article and has participated in interstate licensure mechanisms; the details of coverage, modality requirements, and licensure pathways have changed several times since 2020, so the Board's current published guidance is the authoritative source rather than any third-party summary.

The practical consequence is that a peptide prescription reaching a Maryland address typically involves at least four overlapping authorities: the FDA (the product), the Maryland Board of Physicians (the prescriber), the Maryland Board of Pharmacy (the dispensing or compounding pharmacy, including non-resident permit holders), and — for scheduled substances only — DEA and the state CDS program.

Who Enforces What

Adverse Events in the Peptide Literature: What Studies Report

Regulatory categories matter partly because the safety evidence differs so sharply between approved and unapproved peptides. The largest body of published safety data concerns GLP-1 receptor agonists, and most of it comes from pharmacovigilance databases — spontaneous reporting systems that detect signals but cannot establish incidence or causation.

Gastrointestinal signals

A disproportionality study using the FDA Adverse Event Reporting System (FAERS) examined GLP-1 receptor agonists as a class and reported gastrointestinal adverse reaction signals across the agents studied (PMID 36568085). A separate FAERS analysis focused on semaglutide reported gastrointestinal adverse events as a prominent reporting category for that drug (PMID 36339230). A later post-marketing disproportionality analysis of semaglutide reviewed the broader spectrum of reported events beyond the gastrointestinal tract (PMID 38943656).

Pancreatitis and metabolic signals

Researchers combining a case series with real-world pharmacovigilance analysis examined the association between different GLP-1 receptor agonists and acute pancreatitis (PMID 39605914). Another pharmacovigilance study looked specifically at metabolic and nutritional adverse events reported for this drug class (PMID 39040467). Tirzepatide's real-world safety profile has been characterised in its own FAERS analysis (PMID 39141075).

Psychiatric signals

A pharmacovigilance analysis of individual case safety reports submitted to the European EudraVigilance database examined psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide (PMID 38265519). A FAERS-based study explored the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviours (PMID 38355513). Both were signal-detection exercises rather than controlled trials, and the authors of such analyses routinely note that reporting biases limit interpretation.

Musculoskeletal and performance peptides

For the peptides most often marketed for injury recovery or athletic performance, the evidence base is far thinner. A review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance assessed the safety and efficacy evidence for these compounds and distinguished those with regulatory approval from those without (PMID 41966639). That approved-versus-unapproved distinction maps directly onto the regulatory layers described above: the unapproved compounds are the ones that circulate as research-use-only material, outside the pharmacovigilance systems that generated the GLP-1 data.

Reading Claims Critically

Several features recur in marketing that does not survive contact with the primary literature:

1. Animal or in-vitro findings presented as human results. Much peptide enthusiasm rests on preclinical work that has not been replicated in humans.
2. Pharmacovigilance signals described as either proof of harm or proof of safety. Disproportionality analyses identify reporting patterns; they do not measure risk.
3. Compounded products described as equivalent to approved ones. Analytical work has shown that process and compounding steps affect product attributes (PMID 39379664).
4. State-specific legal claims without a citation. As noted, no peptide-specific Maryland statute is publicly citable; general drug and pharmacy law applies.

Readers with questions about a specific product, prescription, or business arrangement in Maryland should direct them to the Maryland Board of Pharmacy, the Maryland Board of Physicians, or a licensed attorney. Clinical questions belong with a licensed physician. Nothing on this page is legal advice or medical advice.

References

• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database (International Journal of Clinical Pharmacy, 2024)
• The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (Journal of Endocrinological Investigation, 2024)
• Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database (Frontiers in Endocrinology, 2022)
• A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data (Journal of Diabetes Investigation, 2024)
• Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events (Frontiers in Pharmacology, 2024)
• Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis (Frontiers in Pharmacology, 2024)
• Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database (BMC Medicine, 2024)
• Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs (Pharmaceutical Research, 2024)
• 2017 FDA Peptide Harvest (Pharmaceuticals, 2018)
• Weight loss and body composition after compounded semaglutide treatment in a real world setting (Diabetes, Obesity & Metabolism, 2025)
• Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (Frontiers in Public Health, 2022)